SLU-PP-332 supplements: what the capsule sellers aren't telling you

What did @vitaminershop actually say?

The spoken transcript here is just Nina Simone lyrics. The real pitch lives in the caption, where @vitaminershop describes SLU-PP-332 as applying "the same science" as SARMs to promote "muscle hypertrophy and fat reduction without the side effects of classic anabolics." That's a lot of weight to hang on a compound that has never been tested in a human being. The lyrics themselves say nothing, but the product copy says plenty, and that's what deserves scrutiny.

Does the science back this up?

Not in any way that justifies selling capsules to consumers. SLU-PP-332 is a synthetic ERR (estrogen-related receptor) agonist, not a SARM at all. The caption misidentifies the mechanism entirely. The compound was developed at Washington University in St. Louis and published by Zuercher et al. (2019, Journal of Medicinal Chemistry) as a research probe for studying ERRα, ERRβ, and ERRγ. A 2023 mouse study from the same group (Brown et al., Cell Metabolism) showed improved exercise endurance and metabolic changes in rodents, which is genuinely interesting. However, rodent metabolic data does not translate directly to human outcomes, and no Phase I safety trial exists. Calling this "proven science" is a stretch that the actual researchers would not make.

• All published data is preclinical (rodent models only).
• The compound targets ERR receptors, not androgen receptors. The SARM comparison in the caption is mechanistically incorrect.
• No human pharmacokinetic data, no established safe dose range, no long-term safety profile exists in any peer-reviewed source.

What did they get wrong (or right)?

They got the receptor system wrong. SARMs bind androgen receptors selectively. SLU-PP-332 does not. It activates ERRα/β/γ, which are involved in mitochondrial biogenesis and oxidative metabolism. Describing it as applying "SARM science" is not a simplification, it is a factual error that misrepresents how the compound works. That matters because the risk profiles of androgen-receptor modulators and ERR agonists are completely different categories of pharmacology.

What they got partially right: there is legitimate preclinical research showing metabolic effects. Brown et al. (2023, Cell Metabolism) reported that mice given SLU-PP-332 showed increased oxidative muscle fiber expression and ran longer on treadmill tests without additional training. That data is real. But real mouse data is not a green light to sell 60-capsule bottles to humans at 250 mcg doses with zero clinical backing.

What should you actually know?

SLU-PP-332 is a research chemical with zero human safety data. Buying it as a supplement means you are self-experimenting with an uncharacterized compound sold outside any regulatory framework. The FDA does not recognize it as a dietary supplement ingredient, and no country has approved it for human use. The 250 mcg dose listed on the bottle is not derived from human trials because none exist. Supplement sellers often anchor doses to mouse studies after applying a rough body surface area conversion, which is a methodologically questionable practice that ignores human absorption, metabolism, and off-target effects.

If the metabolic and endurance mechanisms in the ERR pathway interest you, there are clinically studied options worth discussing with a licensed provider. Buying unregulated capsules of a compound that has only been injected into mice in controlled lab settings is a different category of decision entirely.